Sheppard, M., Bronstein, M. D., Freda, P., Serri, O., De Marinis, L., Naves, L., . . . Colao, A. (2015). Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary.
শিকাগো স্টাইলে সাইটেশনSheppard, Michael, et al. "Erratum To: Pasireotide LAR Maintains Inhibition of GH and IGF-1 in Patients With Acromegaly for Up to 25 months: Results From the Blinded Extension Phase of a Randomized, Double-blind, Multicenter, Phase III Study." Pituitary 2015.
এমএলএ সাইটেশনSheppard, Michael, et al. "Erratum To: Pasireotide LAR Maintains Inhibition of GH and IGF-1 in Patients With Acromegaly for Up to 25 months: Results From the Blinded Extension Phase of a Randomized, Double-blind, Multicenter, Phase III Study." Pituitary 2015.